News
RLAY
19.74
+4.44%
0.84
Weekly Report: what happened at RLAY last week (0629-0703)?
Weekly Report · 1d ago
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer sells 50,000 shares for $954,500
PUBT · 5d ago
Relay Therapeutics Targets NRAS Cancers With New First-in-Human Trial
TipRanks · 5d ago
Biotech Is The Rate Cut Trade In Disguise
Seeking Alpha · 06/29 21:20
Weekly Report: what happened at RLAY last week (0622-0626)?
Weekly Report · 06/29 09:51
Relay Therapeutics President, R&D Donald Bergstrom disposes of 93,456 common shares valued at $1.58 million
PUBT · 06/24 20:10
Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain
Seeking Alpha · 06/24 19:51
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings
Seeking Alpha · 06/22 13:32
Weekly Report: what happened at RLAY last week (0615-0619)?
Weekly Report · 06/22 09:57
Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Relay Therapeutics (RLAY)
TipRanks · 06/18 09:51
Weekly Report: what happened at RLAY last week (0608-0612)?
Weekly Report · 06/15 09:57
Relay Therapeutics Expands Authorized Shares at 2026 Meeting
TipRanks · 06/09 21:39
Weekly Report: what happened at RLAY last week (0601-0605)?
Weekly Report · 06/08 09:55
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 06/05 03:30
The Prognosis For Palvella Therapeutics
Seeking Alpha · 06/03 18:09
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Eli Lilly & Co (LLY) and Relay Therapeutics (RLAY)
TipRanks · 06/03 12:30
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)
TipRanks · 06/03 11:40
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)
TipRanks · 06/02 19:30
Weekly Report: what happened at RLAY last week (0525-0529)?
Weekly Report · 06/01 09:57
Relay Therapeutics to join Jefferies Global Healthcare Conference fireside chat
PUBT · 05/27 20:08
More
Webull provides a variety of real-time RLAY stock news. You can receive the latest news about Relay Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RLAY
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.